Our Drug Candidates

An Industry-Leading Uro-Oncology Pipeline

Our pipeline has the potential to transform existing treatment paradigms across a number of uro-oncological conditions, including low-grade UTUC and non-muscle invasive bladder cancer (NMIBC), to make outpatient drug therapy a potential first-line treatment option for these patients suffering from cancers currently treated exclusively with surgical intervention.

Pipeline

CATEGORYPROGRAMPRE-CLINICALPHASE 1PHASE 2PHASE 3
Uro-oncologyUGN-101 (Orphan) 
Low-Grade Upper Tract
Urothelial Carcinoma (UTUC)


UGN-102 
Low-Grade Non-Muscle Invasive
Bladder Cancer (NMIBC)

Immuno-
Uro-oncology
UGN-201 
Carcinoma in Situ (CIS)
Bladder Cancer
NeuromodulationBotuGel1 
Overactive Bladder

1 Licensed to Allergan

The above product candidates in development are investigational. The safety and efficacy of such investigational product candidates has not been established.

Contact

UroGen Pharma
499 Park Avenue, Suite 1200
NY 10022, U.S.A
+1-646-768-9780 ext 1001